data stringlengths 286 4.58k | criteria stringlengths 53 12.9k |
|---|---|
Study Objectives
This phase II trial is studying the side effects and how well pazopanib works in treating patients with metastatic urothelial cancer. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Conditions: Distal Urethral... | Inclusion Criteria:
* Histologically or cytologically confirmed transitional cell cancer of the urothelium or bladder
* Metastatic disease
* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 2.0 cm by conventional techniques OR ≥ 1.0 cm by spiral CT scan
* No known brain metastases
* ECOG perf... |
Study Objectives
This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either gefitinib or erlotinib... | Inclusion criteria:
1. Patients with pathologic confirmation of NSCLC Stage III-B (with pleural effusion) or Stage IV adenocarcinoma who have failed at least one but not more than two lines of cytotoxic chemotherapy (including adjuvant chemotherapy). One of the chemotherapy regimens must have been platinum-based.
2. P... |
Study Objectives
Purpose: To evaluate reactions to and opinions of a messaging campaign.
Participants: Participants will be recruited through Prime Panels and will be US-based adults (18 years old and older) who consumed red meat in the past 30 days.
Procedures (methods): After completing a screening question about m... | Inclusion Criteria:
* Be 18 years or older
* Be able to read and speak English
* Be able to take a computer survey in English
* Currently reside in the United States
* Consumed red meat in the past 30 days
Exclusion Criteria:
* Non red-meat eater |
Study Objectives
The purpose of this study is to examine reports of the cancer called hepatosplenic T-cell lymphoma (HSTCL) in the Dutch National Database of Pathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief or PALGA) during the years 1995 to 2008.
Conditions: Hepatosplenic T-cell Lymphoma
Interven... | Inclusion Criteria:
- Patients diagnosed with HSTCL in the Dutch National Database of Pathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief) database during the years 1995 to 2008
Exclusion Criteria:
- Patients who are not diagnosed with HSTCL |
Study Objectives
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
Conditions: Lymphoma, Non-Hodgkin's
Intervention / Treatment:
DRUG: lenalidomide
Location: Spain, France, Germany, I... | Key Inclusion criteria
* Biopsy proven aggressive non-hodgkin's lymphoma
* Follicular center lymphoma Grade 3.
* Diffuse large B-cell lymphoma.
* Mantle cell lymphoma.
* Transformed lymphoma.
* Relapsed or refractory to previous therapy for lymphoma
* At least one prior combination chemotherapy regime
* Measu... |
Study Objectives
The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.
Conditions: Squamous Cell Carcinoma of the Head and Neck
Intervention / Treatment:
D... | For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
* Men and women ≥ 18 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
* Histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx), ... |
Study Objectives
This Observational Registry study is designed to collect self-reported Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program-enrolled patient experience with breakthrough cancer pain (BTcP) as a result of treatment with Abstral® through the use of ... | Inclusion Criteria:
* All patients 18 years of age and older with breakthrough cancer pain who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician... |
Study Objectives
Deep learning technology has an increasing role in medical image applications and, recently, an artificial intelligence device has been developed and commercialized by Medtronic for identification of polyps during colonoscopy (GI-GENIUS). This kind of computer-aided detection (CADe) devices have demons... | Inclusion Criteria:
* Individuals with a positive result in fecal immunochemical test within the population-based colorectal cancer screening program.
* Complete colonoscopy with cecal intubation.
* Inform consent signed.
Exclusion Criteria:
* Personal history of colorectal cancer.
* Family history of colorectal can... |
Study Objectives
This study explores the feasibility of sentinel lymph node identification in pharynx and larynx cancers using flexible endoscopy-guided tracer injection.
Conditions: Head and Neck Cancer, Lymph Node Metastases
Intervention / Treatment:
PROCEDURE: Radioactive tracer injection via flexible endoscopy an... | Inclusion Criteria:
* Male or female aged \>18 years.
* Mucosal tumor of the oropharynx, hypopharynx or larynx.
* Patients planned to undergo biopsy via flexible endoscopy.
* Patients planned to undergo curative radiotherapy with or without concurrent chemotherapy.
* Patient provided written informed consent.
Exclusi... |
Study Objectives
Breast cancer is the first female cancer in France. Total mastectomy occurred in 30% of breast cancer patient population.
The purpose of this study is to evaluate the feasibility of outpatient surgery for the total mastectomy.
In France, Ambulatory care is developed as part of the new national health... | Inclusion Criteria:
* All patient with an indication of breast non conserving surgery
Exclusion Criteria:
* Standard contra-indication for ambulatory care.
* Also bilateral surgery and immediate breast reconstruction. |
Study Objectives
Phase I trial aimed to determine the Maximum Tolerable Dose of the BV in combination with ESHAP in relapsed/resistant Hodgkin Lymphona patients and to evaluate response to treatment with BV-ESHAP as salvage regimen prior to autologous stem cell transplantation.
Conditions: CLASSICAL HODGKIN LYMPHOMA
... | Inclusion Criteria:
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
* Histologically confirmed relapsed or refractory classical HL after first line chemotherapy. CD30 has to be positive
* Age 18 to 65 years. Patient... |
Study Objectives
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura.
PURPOSE: Randomized phase III trial to compare the ef... | DISEASE CHARACTERISTICS: Histologically confirmed malignant mesothelioma of the pleura not amenable to curative surgery Must be radiologically accessible Unidimensionally or bidimensionally measurable disease Pleural effusions or positive bone scan not considered measurable No brain metastases
PATIENT CHARACTERISTICS:... |
Study Objectives
This will be a multicenter, open-label study enrolling a total of up to 23 patients.
Conditions: Metastatic Colorectal Cancer
Intervention / Treatment:
DRUG: bevacizumab, DRUG: FOLFOX, DRUG: PRO95780
Location:
Study Design and Phases
Study Type: INTERVENTIONAL
Phase: PHASE1
Primary Purpose: TREATM... | Inclusion Criteria:
* Histologically confirmed CRC with evidence of locally advanced recurrent or metastatic disease and measurable tumor lesions
* Life expectancy \> 3 months
* For patients of reproductive potential (males and females), use of reliable means for contraception throughout the trial and for 6 months fol... |
Study Objectives
This two-part study is designed to select the subcutaneous (SC) dose of Herceptin that results in comparable exposure to intravenous (IV) Herceptin in healthy male participants and in HER2-positive female participants. The study will also assess the safety and tolerability of the SC and IV formulations... | Inclusion Criteria:
* Healthy Participants (Part 1 only)
* Males 18 to 45 to years of age
* Baseline left ventricular ejection fraction (LVEF) greater than (\>) 60 percent (%)
* HER2-Positive Females (Parts 1 and 2)
* Females greater than or equal to (≥) 18 years of age
* Eastern Cooperative Oncology Group (... |
Study Objectives
Ductal adenocarcinoma is the most frequent pancreatic solid lesion and the most common tumor of the pancreas. Given its poor prognosis and the major therapeutic consequences, the discrimination between PA and other pancreatic solid lesions is mandatory. EUS is admitted as the most sensitive imaging pro... | Inclusion Criteria:
* patients with a solid pancreatic mass of indeterminate origin
Exclusion Criteria:
* presence of a cystic component greater than 25 % of the total volume of the lesion, pregnancy, lactation, age \<18 years, and usual contraindications to SonoVue® injection |
Study Objectives
The aim of this study is to evaluate the analgesic efficacy and safety of adding dexmedetomidine versus dexamethasone to levobupivacaine in ultrasound guided ESPB for patients undergoing modified radical mastectomy
Conditions: Breast Cancer, Post Operative Pain
Intervention / Treatment:
PROCEDURE: Ad... | Inclusion Criteria:
* Type of surgery; Modified Radical Mastectomy (MRM)
* Physical status ASA II, III.
* Age ≥ 18 and ≤ 65 Years.
* Body mass index (BMI): \> 20 kg/m2 and \< 35 kg/m2.
Exclusion Criteria:
* Patient's refusal
* Age \<18 years or \>65 years
* BMI \<20 kg/m2 and \>35 kg/m2
* Known sensitivity or contra... |
Study Objectives
This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, c... | Inclusion Criteria:
* Subjects with pathologic evidence of an anaplastic oligodendroglioma or mixed glioma (i.e. oligoastrocytoma) are eligible; histopathologic diagnosis will be made using World Health Organization classification criteria; to qualify as a mixed tumor there must be a minimum of 25% oligodendroglial el... |
Study Objectives
The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different 'hi... | Inclusion Criteria:
1. A signed and data informed consent
2. Willing to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
3. 18 years of age or older at time of informed consent
4. Have one or more clinically suspicious lesions for BCC at Pre-Study screening Visit that has:
... |
Study Objectives
This phase II trial is studying how well selumetinib works in treating patients with papillary thyroid cancer that did not respond to radioactive iodine. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions: Recurrent Thyroid Gland Carcinoma... | Inclusion Criteria:
* Histologically or cytologically confirmed papillary thyroid cancer or papillary thyroid cancer with follicular elements
* No longer amenable to radioactive iodine therapy or curative surgical resection
* Tumor is no longer iodine avid
* Tumor did not respond to the most recent radioactive io... |
Study Objectives
The purpose of the study is to evaluate the efficacy and safety of eribulin mesylate in subjects with soft tissue sarcoma who received at least one standard chemotherapy (an anthracycline or an ifosfamide monotherapy or a combination therapy).
Conditions: Soft Tissue Sarcoma
Intervention / Treatment:... | Inclusion Criteria
* Histologically or cytologically confirmed soft tissue sarcoma of high or intermediate grade
* Documented evidence of advanced or metastatic soft tissue sarcoma, not amenable to surgery or radiotherapy
* Within 6 months from the radiographic evidence of disease progression by RECIST criteria in the... |
Study Objectives
AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to pro... | Inclusion Criteria:
* Advanced myeloma, with measurable disease as defined in the protocol.
* Prior treatment, at least 2 prior regimens are required. This may include prior treatment with investigational products.
* Able to perform the activities of daily living.
* Off prior therapy for at least 2-4 weeks depending o... |
Study Objectives
RATIONALE: Lymphadenectomy may remove cancer cells that have spread to nearby lymph nodes. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether conventional surgery is more effective with or without lymphadenectomy and/or radiation therapy in treating endometrial... | DISEASE CHARACTERISTICS:
Surgical randomization:
* Histologically confirmed endometrial carcinoma
* Disease thought preoperatively to be confined to the uterine corpus
Radiotherapy randomization:
* Must have disease determined postoperatively to be confined to the uterine corpus, irrespective of pelvic node status
... |
Study Objectives
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill the tumor cells. Combining chemotherapy with interl... | DISEASE CHARACTERISTICS:
* Histologically confirmed Kaposi's sarcoma (KS)
* HIV positive
* Evaluable disease involving the skin and/or viscera
* At least 5 lesions not previously treated with local therapy if restricted to the skin
* Pulmonary lesions evaluable by CT scan
* Gastrointestinal lesions evaluable by... |
Study Objectives
Single-arm study to determine disease control rate in second- (or later) line treatment with cabazitaxel after the failure of palliative primary treatment.
Conditions: Gastric Cancer
Intervention / Treatment:
DRUG: Cabazitaxel
Location: Germany
Study Design and Phases
Study Type: INTERVENTIONAL
Pha... | Inclusion Criteria:
1. Histologically confirmed inoperable and/or metastatic adenocarcinoma of the oesophagogastric junction or stomach
2. Progression of a measurable lesion (RECIST) on previous palliative chemotherapy. Neoadjuvant/adjuvant treatment is not counted, unless progression occurs \< 6 months after completi... |
Study Objectives
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's blood cells to kill multiple myeloma cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of interleukin-12 given at different times in treating patients with multiple mye... | DISEASE CHARACTERISTICS: Histologically proven plateau phase multiple myeloma at original diagnosis: Bone marrow plasmacytosis with greater than 10% plasma cells, sheets of plasma cells, or biopsy proven plasmacytoma Must be in stable plateau phase requiring objective response, no evidence of continuing improvement by ... |
Study Objectives
The objective of the study is to determine the efficacy and toxicity of sorafenib in metastatic uveal melanoma.
The main objective is to determine the non-tumor progression rate 24 weeks after initiation of treatment with sorafenib at a dose of 800 mg / day
Conditions: Uveal Melanoma
Intervention / ... | Inclusion Criteria:
* Male or female over 18 years old suffering from uveal melanoma with metastasis
* At least one measurable metastases by more than 10 mm acoording to Response Evaluation Criteria in Solid Tumors (RECIST)
* At least 28 days from the previous treatment (systemic or major surgery)
* Performance Index ... |
Study Objectives
The aim of our study is to investigate the effects of a combined treatment of alpha-lipoic acid and myoinositol on clinical, endocrine and metabolic features of women affected by PCOS. The study Group included 40 patients treated with a combined therapy of alpha-lipoic acid (800 mg), myoinositol (2000 ... | Inclusion Criteria:
* women with PCOS in accordance with Rotterdam criteria
Exclusion Criteria:
* pregnancy
* past history of cardiovascular disease,
* diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 g oral glucose tolerance test),
* hypertension,
* significant liver or renal impairme... |
Study Objectives
The purpose of this study is to see if Glad Press 'n Seal works as a moisture barrier for central line that is left in place during ambulatory oncology clinical care.
Conditions: Cancer-related Problem/Condition, Ambulatory Care
Intervention / Treatment:
DEVICE: Glad Press 'n Seal
Location: United S... | Inclusion Criteria:
* Subjects requiring mediport or peripherally inserted central venous catheter line access for 3-5 days
* Able to read and write English
* Use showering as a means of home hygiene
Exclusion Criteria:
* Subjects with eczema/psoriasis at the line insertion area
* Subjects with active line/site irri... |
Study Objectives
The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.
Conditions: Keratosis, Actinic
Intervention / Tr... | Inclusion Criteria:
* At least 6 Grade 1/2 AKs on one upper extremity AND
* At least 12 Grade 1/2 AKs on the OTHER upper extremity
Exclusion Criteria:
* Pregnancy
* history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis
* lesions suspicious for skin cancer (skin cancer ... |
Study Objectives
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
Conditions: Sarcoma, Kaposi, HIV Infections
Intervention / Treatment:
DRUG: Tecogalan sodium
Location: United States
Study Design and Phase... | Inclusion Criteria
Patients must have:
* Kaposi's sarcoma plus HIV infection OR metastatic solid tumor.
* Life expectancy of at least 12 weeks.
* NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks.
* Recovered from toxicity of any prior anticancer therapy.
Exclusion Criteria
Co-existing Co... |
Study Objectives
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
Conditions: Acute Myelogenous Leukemia
Intervention / Treatment:
DRUG: Decitabine, DRUG: Vorinostat, DRUG: Filgrastim (G-CSF), DRUG: Fludarabine, DRUG: Cytarabine
Locat... | Inclusion Criteria:
- Patients must be ≥ 1 and ≤25 years of age.
Diagnosis: Patients with relapse or refractory AML must have measurable disease ( \>M1 marrow)
* 1st or greater relapse, OR
* Failed to go into remission after 1st or greater relapse, OR
* Failed to go into remission from original diagnosis after 2 or ... |
Study Objectives
This is an open-label, Phase 1, dose escalation study of oral ARQ 736 administered to subjects with advanced solid tumors harboring the mutation. The study is designed to explore the safety, tolerability, pharmacokinetics and pharmacodynamics of ARQ 736 and to define a recommended Phase 2 dose of ARQ 7... | Inclusion Criteria:
* Signed written informed consent granted prior to initiation of any study-specific procedures
* Male or female subjects of ≥ 18 years of age
* All subjects must be positive for a BRAF and/or NRAS mutation
* Histologically or cytologically confirmed locally advanced, inoperable or metastatic solid ... |
Study Objectives
Bronchopulmonary cancer is the first cause of mortality in the world. We want to update the margins used in stereotactic radiotherapy, in the context of localized lung cancer, of non-surgical management.
The investigators wish to redefine the stereotactic radiotherapy margins according to the histolog... | Inclusion criteria:
* Major subject (≥18 years old)
* Subject operated on at HUS for T1/T2a N0 stage lung adenocarcinoma or squamous cell carcinoma before 30/09/2019
* CT scan available on the HUS imaging server or on CD
* Subject who has not expressed opposition to the use of his or her data for research purposes
Ex... |
Study Objectives
Organ transplant recipients (OTR) have an increased risk of non-melanoma skin cancer, in particular squamous cell carcinoma (SCC), often developing in areas of field cancerization, areas with multiple precancerous actinic keratoses. The risk of developing SCC in OTR is 65-100-fold the normal population... | Inclusion Criteria:
* Multiple actinic keratoses (\>5) in two symmetrical areas on each side of the scalp or forehead
* OTR with stable graft function
* More than eighteen years of age
* Written informed consent
Exclusion Criteria:
* Allergy to the MetvixR cream
* Previous PDT treatment less than 6 months ago in tre... |
Study Objectives
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well doxorubicin hydrochloride liposome works as firs... | DISEASE CHARACTERISTICS:
* Histologically confirmed invasive ductal or lobular adenocarcinoma of the breast
* Metastatic disease as confirmed by ≥ 1 of the following:
* Histology or cytology
* Radiology
* Elevated CA 15-3 levels
* No HER2/neu overexpression by IHC or FISH
* Measurable (≥ 10 mm) or eval... |
Study Objectives
The research hypothesis is that topical application of a mixture of pre-polymers of polypropylene glycol and polyethylene glycol (an optical clearing agent) will reduce skin light scattering, increasing the amount of light reaching the target for diagnostic as well as therapeutic purposes.
Conditions:... | Inclusion Criteria:
* Adult 18 years and older
* Lesion diagnoses in an area measuring 3 cm2 or more on any body site
* Apparent good health
Exclusion Criteria:
* Pregnant women
* History of cutaneous photosensitivity
* History of photodermatoses |
Study Objectives
That computed tomography (CT) screening of HIV-seropositive heavy smokers will detect early stage lung cancer at significantly higher rates than what is currently being observed.
Conditions: Lung Cancer in the HIV Patient, HIV Infections, HIV Seropositivity, Lung Cancer
Intervention / Treatment:
DEVI... | * Age over 25 years old.
* Confirmed HIV seropositive by ELISA assay
* No woman who has a positive serum pregnancy
* Current or previous cumulative cigarette smoking history of \> 20 pack years
* Former smokers must have quit smoking within the previous 15 years.
* No medical or psychiatric condition precluding informe... |
Study Objectives
The purpose of this study is to test a novel dendritic cell (DC) vaccine in patients with Stage IV melanoma.
Conditions: Melanoma, Neoplasm Metastasis
Intervention / Treatment:
BIOLOGICAL: Dendritic cell vaccination
Location: United States
Study Design and Phases
Study Type: INTERVENTIONAL
Phase: P... | Inclusion Criteria:
* Stage M1a, M1b, M1c biopsy proven metastatic melanoma
* Failure of at least one prior chemotherapy regimen of DTIC and/or temozolomide with/without interleukin-2 (IL-2).
* Karnofsky performance status greater than/equal to 80%.
* Measurable metastatic lesions by physical exam or scans.
* Acceptab... |
Study Objectives
This trial compares induction treatment with FOLFOX with or without aflibercept in a high risk population selected by MRI, prior to receiving standard chemoradiation (capecitabine combined with 50.4 Gy in 28 days) and surgery, in order to evaluate the efficacy in terms of pathologic complete response (... | Inclusion Criteria:
1. Signed and dated informed consent, and willing and able to comply with protocol requirement;
2. Male or female subjects with rectal cancer ≥18 and \<70 years of age;
3. High risk MRI-defined operable rectal cancer (with an inferior margin no more than 12 cm above the anal verge as assessed by MR... |
Study Objectives
THE EFFECT OF BLACK MULBERRY LOLLIPOP AND SODIUM BICARBONATE USED IN ORAL CARE ON PREVENTION OF ORAL MUCOSITIS AMONG CHILDREN RECEIVING CHEMOTHERAPY DUE TO CANCER
Conditions: Oral Mucositis
Intervention / Treatment:
OTHER: Oral Mucositis
Location: Turkey
Study Design and Phases
Study Type: INTERVEN... | Inclusion Criteria:
* Being in the age group of 3-18 years
* Being hospitalised for chemotherapy treatment
* Not having oral mucositis
* No using another method to protect oral mucosa during the study period
* Not having the history of black mulberry (similar fruit berries, blackberries, etc.) allergy
* Not having int... |
Study Objectives
The purpose of this study is to explore the experiences of Black women who receive care for ovarian cancer at Memorial Sloan Kettering Cancer Center, or "MSK" for short. The study consists of interviews with Black women who recently obtained some part of their ovarian cancer care at MSK.
Conditions: O... | Inclusion Criteria:
* Participant must have been diagnosed with ovarian, fallopian tube or primary peritoneal cancer and treated by an MSK physician.
* Participants must be able to provide verbal informed consent.
* Participants must be 18 years of age or older.
* Participants must self-identify as Black/African Ameri... |
Study Objectives
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.
Conditions: Gastric Cancer
Intervention / Treatmen... | DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed gastric or gastroesophageal junction carcinoma (gastric carcinoma closed to accrual as of 02/04)
* Must have received 1 or 2 prior chemotherapy regimens for gastric carcinoma (gastric carcinoma closed to accrual as of 02/04)
* Bidimensionally measura... |
Study Objectives
This is a multi-centre prospective, non-inferiority trial. Patients will be randomized to two treatment groups in a 1:1 ratio and will be stratified by age, Karnofsky Performance Status and extent of the surgical resection.
This study will assess the effect of a one-week radiotherapy regimen in compar... | Inclusion Criteria:
* Histopathologically confirmed newly diagnosed glioblastoma multiforme (GBM, WHO grade IV). The histological diagnosis must have been made locally after biopsy or neurosurgical tumour resection.
* Initial surgery/biopsy at diagnosis performed \< 6 weeks (42 days) prior to randomization.
* Patient'... |
Study Objectives
The primary purpose of this study is to determine whether educational workshops paired with self-collected high-risk human papillomaviruses (hrHPV) screening will increase participation in cervical cancer screening among Southeast Asian Immigrant and Refugee populations in Wisconsin compared with offer... | Inclusion Criteria:
* Fluent understanding in English, Hmong, Karen, Burmese, or Karenni
Exclusion Criteria:
* Prior hysterectomy
* Impaired decision-making capacity
* Pregnancy |
Study Objectives
The purpose of this study is to determine the pharmacokinetics of oral Ixabepilone.
Conditions: Cancer
Intervention / Treatment:
DRUG: Ixabepilone, DRUG: Ixabepilone, DRUG: Ixabepilone
Location: United States
Study Design and Phases
Study Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Primary Purpose: ... | Inclusion Criteria:
* ECOG status of 0-2.
Exclusion Criteria:
* Unable to swallow pills.
* Current or recent GI disease or GI surgery.
* Brain mets.
* Severe nerve damage.
* ANC \<1,500/mm3
* Platelets \<125K.
* Bilirubin \>=1.5 times the IULN.
* ALT/AST \>=1.5 times the IULN.
* Creatine \>1.5 times the IULN.
* Prio... |
Study Objectives
This phase I clinical trial studies the safety and best dose of selumetinib and cixutumumab in treating patients with advanced solid malignancies. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block... | Inclusion Criteria:
* Patients must have a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist
* There is no limit on the number of prior treatment regimens
* Patients must ... |
Study Objectives
Recurrence after endoscopic mucosal resection of laterally spreading lesions (LSL) \>= 20mm in size occurs in approximately 20% of cases at surveillance colonoscopy. We aim to evaluate the efficacy of prophylactic adjuvant thermal ablation of the EMR mucosal defect margin in reducing adenoma recurrence... | Inclusion Criteria:
* Referred for removal of a colonic polyp \>= 20mm in size
* Able to give informed consent to involvement in trial
Exclusion Criteria:
* Younger than 18 years of age
* Highly dependant on medical care
* Women who are pregnant or may be pregnant.
* Taken clopidogrel within 7 days
* Taken warfarin ... |
Study Objectives
This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back (recurrent), have not responded to treatment (refractory), or are growing... | Inclusion Criteria:
* Patients must have a body surface area (BSA) \>= 0.4 m\^2 at the time of study enrollment
* Patients must have a pilocytic astrocytoma or optic pathway glioma that has relapsed, progressed, or become refractory to conventional therapy; patients with neurofibromatosis (NF-1) are eligible
* Patient... |
Study Objectives
To investigate the effect of metformin on pregnancy complications and pregnancy outcome in the II. and III. trimester of pregnancy in women with polycystic ovary syndrome.
Conditions: Polycystic Ovary Syndrome
Intervention / Treatment:
DRUG: Metformin, DRUG: Placebo
Location: Norway
Study Design an... | Inclusion Criteria:
* 18-45 years,
* PCOS diagnosis according to Rotterdam criteria
* single, viable, ultrasound verified fetus
* if metformin was used at conception and early pregnancy, at least 7 days of "wash out"
Exclusion Criteria:
* known liver disease or ALAT \> 90 nmol/L
* known renal disease or creatinine \... |
Study Objectives
The initial intent of the study was to be a multi-center single-arm open-label Simon's two-stage Phase II clinical trial of first-line mFOLFOX6 + trastuzumab + avelumab in metastatic HER2-amplified gastric and esophageal adenocarcinomas.
Accrual will halt after completion of Stage I (enrollment of 18 ... | Inclusion Criteria:
1. Written informed consent and HIPAA authorization for release of personal health information prior to registration.
2. Age ≥ 18 years at the time of consent.
3. ECOG Performance Status of 0 or 1.
4. Histologically confirmed esophageal, gastroesophageal junction, or gastric adenocarcinoma, with un... |
Study Objectives
This study will evaluate the impact of Xiapex treatment on the range of motion (ROM) of the affected fingers and the patient and physician reported treatment satisfaction and disease severity and their relation to ROM. Recovery to normal activities, recovery time (How long overall, time to use hand, ti... | Inclusion Criteria:
* Presenting with a Dupuytren's contracture of at least 20 degrees caused by a palpable cord in at least one finger other than the thumb.
* Positive "table top test" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
Exclusion Criteria:
* Re... |
Study Objectives
This is a prospective, non-interventional study of adult patients prescribed topical treatment with ingenol mebutate gel (Picato®) as part of provision of care for the treatment of Non-hyperkeratotic, non-hypertrophic Actinic Keratosis (AK). Patients with complete clearance at 8 weeks will be followed ... | Inclusion Criteria:
* Planned to receive topical ingenol mebutate gel for treatment of Actinic Keratosis according to current labelling in Greece.
* Written informed consent obtained to use the patient's data for the study.
Exclusion Criteria:
* Contraindications according to prescribing information.
* Previous trea... |
Study Objectives
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients respond to treatment.
PURPOSE: This laboratory study is looking at... | DISEASE CHARACTERISTICS:
* Diagnosis of acute myeloid leukemia
* Enrolled on clinical trial ECOG-E1900
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified |
Study Objectives
This study evaluates the addition of valproic acid as a chemopreventive drug in head and neck squamous cell carcinoma (HNSCC) patients that do not have signs of recurrence or residual disease. The participants will be randomized 1:1 (valproic acid : placebo). The primary outcome is to document histone ... | Inclusion Criteria:
* Patients that signed the formal consent;
* Previous history of head and neck squamous cell carcinoma with no more than three years of follow-up;
* History of squamous cell carcinoma in the following sub-sites: oral cavity, oropharynx, larynx and hypopharynx;
* Absence of active malignant disease ... |
Study Objectives
Weaning of mechanically ventilated patient is a daily challenge in Intensive Care units. Several indexes have been employed to assess the patient's ability to recover efficient spontaneous breathing. As the diaphragm is the main respiratory muscle, direct measurement of diaphragmatic function as predic... | Inclusion Criteria:
* Age18-65 years.
* ASA class 1 to 3,
* body mass index (BMI) between 20 and 40 kg/m2
* intubation for ≥ 48 hours
* Types of abdominal cancer surgery included partial gastrectomy, hysterectomy, Splenectomy, hepatectomy, and colectomy.
Exclusion Criteria:
* Hemodynamic instability requiring vasopr... |
Study Objectives
Primary Objectives:
* To determine the maximum tolerated dose, and dose limiting toxicities of cabazitaxel administered as a 1-hour infusion every 3 weeks in combination with oral daily abiraterone acetate and prednisone in participants with metastatic Castrate-resistant prostate cancer (CRPC)
* To es... | Inclusion criteria :
* Diagnosis of prostate adenocarcinoma proven histologically or cytologically, resistant to hormone therapy and previously treated with a docetaxel-containing regimen. In Phase 2 part, participants should have been treated with abiraterone acetate for at least 3 months and should continue treatmen... |
Study Objectives
The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).
Conditions: Neoplasms, Neopl... | Inclusion Criteria:
* Confirmed diagnosis of advanced, refractory breast or prostate cancer that is evaluable by radiologic testing. Participants must have experienced tumor progression on or treatment intolerance to at least one prior therapy.
* For participants with metastatic castrate-resistant prostate cancer only... |
Study Objectives
Peripheral blood mononuclear cells (PBMC) will be collected from patients who have leukemia or lymphoma or other medical conditions involving altered lymphohematopoietic stem cell or immunological function. These PBMC will be assessed for cellular markers by flow cytometry and will be studied for in vi... | Patients obtained from collaborators within and outside the NCI. |
Study Objectives
The purpose of this research study is to determine the best way to increase screening for cervical cancer, colorectal cancer, HIV, and Hepatitis C among under screened Hispanic, Haitian and African-American individuals in Hialeah, South Dade, and Little Haiti. The investigator will compare home testing... | Inclusion Criteria:
1. live in one of the three target communities
2. self-identify as Haitian, Hispanic and/or Black.
3. be 50-64 years old
4. need at least one of the four recommended screening services as per US Preventive Service Task Force 121 guidelines as follows: never having had a HIV test b) never having had... |
Study Objectives
Oxaliplatin is a cytotoxic platinum compound and is one of the chemotherapeutic agent used in advanced colorectal cancer. It is used combined with Fluorouracil (5 FU) and Leucovorin. The main and most suffering side effect of oxaliplatin is polyneuropathy. Oxaliplatin-induced polyneuropathy (OIPN) can ... | Inclusion Criteria:
* Age ≥ 18 years
* Signed written informed consent.
* Fulfils the indication of the treatment with 3-6 months oxaliplatin combined adjuvant chemotherapy.
* Polyneuropathy grade according to CTCAE before treatment start ≤ 2.
* Performance status according to WHO ≤ 1.
Exclusion Criteria:
* Age \< 1... |
Study Objectives
This is a single center, nonrandom, open-label study aiming to evluate the efficacy and safety of lenvatinib for patients with pretreated advanced biliary tract cancer.
Conditions: Cholangiocarcinoma, Biliary Tract Cancer, Targeted Therapy
Intervention / Treatment:
DRUG: Lenvatinib
Location: China
... | Inclusion Criteria:
* Inclusion Criteria:
1. Pathologically or cytologically confirmed adenocarcinoma of biliary tract cancer (intrahepatic, extrahepatic cholangiocarcinoma, gall bladder cancer), at least one prior chemotherapy.
2. Participants who received adjuvant chemotherapy are eligible if this therapy was c... |
Study Objectives
The poor survival of Veterans with oral cancer underscores the significance of identifying new treatment approaches. The proposed studies will test a new 2 pronged immunotherapeutic approach for oral cancer patients which lessen the immune inhibitory environment while maturing cells that can stimulate ... | Inclusion Criteria:
* locoregional OSCC (T stage II-IV) of the oral cavity, oropharynx, larynx, or hypopharynx without evidence of distant metastases
* greater than or equal to 18 years of age
* the OSCC treatment plan includes surgical resection
* performance status of 0 or 1
* recovered from any prior surgery
* must... |
Study Objectives
This study is a single-armed, open-label, single-center phase II trial of signal transduction inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic melanoma, and aims to study the efficacy and safety. The primary endpoint is progression-free survival (PFS) and the second... | Inclusion Criteria:
1. Histologically confirmed melanoma with metastases and has no received any systemic treatment within 1 month
2. Evidence of mutations and/or copy number increases of KIT with laboratory examination documented from either primary or metastatic tumor site
3. ECOG performance status 0, 1, or 2
4. Es... |
Study Objectives
The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when administered in combination with pembrolizumab.
Conditions: Solid Neoplasms
I... | Inclusion Criteria:
* Has a histologically- or cytologically-confirmed advanced/metastatic solid tumor by pathology report and have received, or been intolerant to, or been ineligible for all treatment known to confer clinical benefit. Participants with solid tumors of any type are eligible for enrollment.
* Has stage... |
Study Objectives
To assess the effectiveness of two anesthetic techniques by measuring the pain through visual analog scale (VAS), to obtain saturation prostate biopsies.
Conditions: Prostatic Cancer
Intervention / Treatment:
DRUG: MIDAZOLAM, DRUG: MEPIVACAÍNE, DRUG: FENTANILE, DRUG: KETAMINE
Location: Spain
Study ... | Inclusion Criteria:
* Male patient
* Persistence of suspected prostate cancer by altering the prostatic specific antigen and / or digital rectal examination.
* Two previous negative prostate biopsies .
* Age \< 75 years.
* Signature of informed consent to perform prostate biopsy.
* Signature of informed consent for th... |
Study Objectives
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor gro... | DISEASE CHARACTERISTICS:
* Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx
* Must have undergone complete macroscopic resection
* Presence of ≥ 1 of the following poor prognostic factors after complete resection:
* Incomplete microscopic resection and N+
* C... |
Study Objectives
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
Conditions: Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies, L... | Inclusion Criteria:
* Patients of more than 18 years of age
* Patients presenting with anemia following chemotherapy
* Patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
-- The patients may be included regardless of their chemotherapy c... |
Study Objectives
Participants with metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy will be randomly assigned to receive Investigator's choice of paclitaxel, docetaxel, or vinflunine (Control), or pembrolizumab. The primary study hypothe... | Inclusion criteria:
* Histologically- or cytologically-confirmed diagnosis of urothelial cancer of the renal pelvis, ureter, bladder, or urethra, that is transitional cell or mixed transitional/non-transitional (predominantly transitional) cell type
* Progression or recurrence of urothelial cancer following a first-li... |
Study Objectives
A randomized controlled trial of a technology-based lifestyle intervention vs. usual care among men with low-risk prostate cancer to determine the feasibility and acceptability of the intervention and the effect of the intervention on behavior change related to exercise, diet, and not smoking.
Conditi... | Inclusion Criteria:
1. clinical stage ≤T3a nonmetastatic prostate cancer within 5 years
2. completion of treatment ≥3 months prior to enrollment, if not on active surveillance
3. ability to walk unassisted
4. be able to speak and read English
5. ability to navigate websites and email, and have internet access
6. able ... |
Study Objectives
The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or breast ultrasound) abnormality will have associated breast cancer at surgical removal of the area.
Condit... | Inclusion Criteria:
* Women 20 years of age or older
* Imaging abnormality necessitating a core needle biopsy
* Core needle biopsy revealing ALH or LCIS
* Patients may have a history of fibroadenoma and/or proliferative breast lesions with atypia
Exclusion Criteria:
* History and/or concomitant diagnosis of invasive... |
Study Objectives
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.
Conditions: Solid Tumors
Intervention / Treatment:
DRUG: Brivanib
Location: Japan
Study Design and Phases
Study Type: INTER... | Inclusion Criteria:
* Patients must have measurable disease
* Documented failure to standard therapies exist, or which are determined to be inappropriate by the investigator
* ECOG PS: 0-1
Exclusion Criteria:
* Subjects with centrally located squamous cell carcinoma of the lung |
Study Objectives
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's lymphocytes to kill kidney cancer cells. Interferon alfa may interfere with the growth of cancer cells. Combining vaccine ther... | Inclusion Criteria:
* Histologically confirmed metastatic renal cell carcinoma with measurable disease.
* Tumor tissue available and properly stored for lysate preparation.
* Patients must be at least 4 weeks from their last immunotherapy, radiation, surgery or chemotherapy (6 weeks for nitrosureas) and recovered from... |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 3